Most Recent
A Melbourne law firm has lost its bid to delay payment of a $184,000 judgment to a former junior lawyer who earned hundreds of thousands of dollars per year under a lucrative pay structure.
The Club of United Business -- a private members club catering to entrepreneurs -- has sued a former membership manager who allegedly used confidential information about clients in order to set up a competing professional networking business.
WA Attorney-General John Quigley wants a second go at his trial testimony in a defamation case brought by mining magnate Clive Palmer, admitting he made "mistakes" while giving evidence in the witness box.
Epic Games has argued in favour of steaming ahead with a trial in its competition case against Apple while its parallel case against Google remains in the embryonic stage, but the tech giants say Google's litigation should catch up in the hopes that the court can hear a joint trial or hold contemporaneous hearings.
SingTel has been blocked from making $190,000 in tax deductions after the Australian Taxation Office won its Federal Court case against the Singaporean teleco over transfer pricing benefits related to the $14.2 billion acquisition of Optus.
King & Wood Mallesons has appointed a former Corrs Chambers Westgarth partner to join its intellectual property practice in Melbourne.
Commenting on the unprecedented nature of the case against her client -- the so-called postbox solicitor in the Banksia Securities class action -- a senior barrister has told a court of her shock at the conduct of her former colleague at the bar, Norman O'Bryan, who acted as lead counsel in the scandal-ridden litigation.
A judge has questioned whether the lead applicant in a class action over sleep apnea machines with alleged safety defects was “appropriately resourced” to run the case against health tech giant Philips.
The former head of money markets at the Australian and New Zealand Banking Group has sued his former employer claiming he was sacked for making complaints about sexual harassment by senior managers at the bank and false reporting to the prudential regulator.
The ACCC has refused to authorise a patent settlement and license agreement between Bristol-Myers Squibb unit Celgene and two generic drug makers who sued to invalidate the patents for its blockbuster cancer drug Revlimid, saying it could distort competition between generic drug makers.